HYPOTHESIS: We hypothesized that supplemental resveratrol would affect glucose metabolism in the skeletal muscle and liver to improve blood glucose control. DESIGN: Case-control study. SETTING: Hospital laboratory. SUBJECTS: Yorkshire miniswine. INTERVENTION: The swine developed metabolic syndrome by consuming a high-calorie, high–fat/cholesterol diet for 11 weeks. Pigs were fed either a normal diet (control) (n = 7), a hypercholesterolemic diet (HCC) (n = 7), or a hypercholesterolemic diet with supplemental resveratrol (100 mg/kg/d) (HCRV) (n = 7). Animals underwent dextrose challenge prior to euthanasia and tissue collection. MAIN OUTCOME MEASURES: Measurements of glucose and insulin levels, skeletal muscle and liver protein expression, and liver function test results. RESULTS: The HCC group had significantly increased blood glucose levels at 30 minutes as compared with the control and HCRV groups. The HCC group demonstrated increased fasting serum insulin levels and levels of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase. Oil red O staining demonstrated increased lipid deposition in the livers of the HCC animals. Immunoblotting in the liver showed increased levels of mammalian target of rapamycin, insulin receptor substrate 1, and phosphorylated AKT in the HCRV group. Immunoblotting in skeletal muscle tissue demonstrated increased glucose transporter type 4 (Glut 4), peroxisome proliferating activation receptor coactivator 1α, peroxisome proliferator-activated receptor α, peroxisome proliferator-activated receptor , and phosphorylated AKT at threonine 308 expression as well as decreased retinol binding protein 4 in the HCRV group. Immunofluorescence staining for Glut 4 in the skeletal muscle demonstrated increased Glut 4 staining in the HCRV group compared with the HCC or control groups. CONCLUSION: Supplemental resveratrol positively influences glucose metabolism pathways in the liver and skeletal muscle and leads to improved glucose control in a swine model of metabolic syndrome.
HYPOTHESIS: We hypothesized that supplemental resveratrol would affect glucose metabolism in the skeletal muscle and liver to improve blood glucose control. DESIGN: Case-control study. SETTING: Hospital laboratory. SUBJECTS: Yorkshire miniswine. INTERVENTION: The swine developed metabolic syndrome by consuming a high-calorie, high–fat/cholesterol diet for 11 weeks. Pigs were fed either a normal diet (control) (n = 7), a hypercholesterolemic diet (HCC) (n = 7), or a hypercholesterolemic diet with supplemental resveratrol (100 mg/kg/d) (HCRV) (n = 7). Animals underwent dextrose challenge prior to euthanasia and tissue collection. MAIN OUTCOME MEASURES: Measurements of glucose and insulin levels, skeletal muscle and liver protein expression, and liver function test results. RESULTS: The HCC group had significantly increased blood glucose levels at 30 minutes as compared with the control and HCRV groups. The HCC group demonstrated increased fasting serum insulin levels and levels of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase. Oil red O staining demonstrated increased lipid deposition in the livers of the HCC animals. Immunoblotting in the liver showed increased levels of mammalian target of rapamycin, insulin receptor substrate 1, and phosphorylated AKT in the HCRV group. Immunoblotting in skeletal muscle tissue demonstrated increased glucose transporter type 4 (Glut 4), peroxisome proliferating activation receptor coactivator 1α, peroxisome proliferator-activated receptor α, peroxisome proliferator-activated receptor , and phosphorylated AKT at threonine 308 expression as well as decreased retinol binding protein 4 in the HCRV group. Immunofluorescence staining for Glut 4 in the skeletal muscle demonstrated increased Glut 4 staining in the HCRV group compared with the HCC or control groups. CONCLUSION: Supplemental resveratrol positively influences glucose metabolism pathways in the liver and skeletal muscle and leads to improved glucose control in a swine model of metabolic syndrome.
Authors: Shaista Malik; Nathan D Wong; Stanley S Franklin; Tripthi V Kamath; Gilbert J L'Italien; Jose R Pio; G Rhys Williams Journal: Circulation Date: 2004-08-23 Impact factor: 29.690
Authors: Sara Heebøll; Karen Louise Thomsen; Steen B Pedersen; Hendrik Vilstrup; Jacob George; Henning Grønbæk Journal: World J Hepatol Date: 2014-04-27
Authors: Ashraf A Sabe; Ahmed A Sadek; Nassrene Y Elmadhun; Rahul S Dalal; Michael P Robich; Cesario Bianchi; Frank W Sellke Journal: J Med Food Date: 2015-01 Impact factor: 2.786
Authors: Jun Wang; Cheuk Tang; Mario G Ferruzzi; Bing Gong; Brian J Song; Elsa M Janle; Tzu-Ying Chen; Bruce Cooper; Merina Varghese; Alice Cheng; Daniel Freire; Amanda Bilski; Jessica Roman; Tuyen Nguyen; Lap Ho; Stephen T Talcott; James E Simon; Qingli Wu; Giulio M Pasinetti Journal: Mol Nutr Food Res Date: 2013-08-21 Impact factor: 5.914
Authors: Ashraf A Sabe; Nassrene Y Elmadhun; Rahul S Dalal; Michael P Robich; Frank W Sellke Journal: J Thorac Cardiovasc Surg Date: 2013-11-20 Impact factor: 5.209
Authors: Thomas K Sin; Bjorn T Tam; Angus P Yu; Shea P Yip; Benjamin Y Yung; Lawrence W Chan; Cesar S Wong; John A Rudd; Parco M Siu Journal: J Gerontol A Biol Sci Med Sci Date: 2015-10-08 Impact factor: 6.053